[go: up one dir, main page]

PE20131397A1 - Terapia de combinacion para tratar infeccion por hcv - Google Patents

Terapia de combinacion para tratar infeccion por hcv

Info

Publication number
PE20131397A1
PE20131397A1 PE2013000657A PE2013000657A PE20131397A1 PE 20131397 A1 PE20131397 A1 PE 20131397A1 PE 2013000657 A PE2013000657 A PE 2013000657A PE 2013000657 A PE2013000657 A PE 2013000657A PE 20131397 A1 PE20131397 A1 PE 20131397A1
Authority
PE
Peru
Prior art keywords
hepatitis
virus
combination therapy
hcv infection
bromo
Prior art date
Application number
PE2013000657A
Other languages
English (en)
Inventor
Wulf Boecher
Carla Haefner
George Kukolj
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131397(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20131397A1 publication Critical patent/PE20131397A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA SERINA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C TAL COMO EL ACIDO 1-{[4-[8-BROMO-2-(2-ISOPROPILCARBAMOIL-TIAZOL-4-IL)-7-METOXI-QUINOLIN-4-ILOXI]-1-(R)-(2-CICLOPENTILOXICARBONILAMINO-3,3-(S)-DIMETIL-BUTIRIL)-PIRROLIDIN-(S)-2-CARBONIL]-AMINO}-2-(S)-VINIL-CICLOPROPANO-(R)-CARBOXILICO QUE SE ADMINISTRA EN UNA CANTIDAD DE 40MG A 480MG POR DIA; B) UN INHIBIDOR DE LA ARN POLIMERASA DEPENDIENTE DE ARN NS5B DEL VIRUS DE LA HEPATITIS C TAL COMO EL ACIDO (E)-3-[2-(1-{[2-(5-BROMO-PIRIMIDIN-2-IL)-3-CICLOPENTIL-1-METIL-1H-INDOL-6-CARBONIL]-AMINO}-CICLOBUTIL)-3-METIL-3H-BENCIMIDAZOL-5-IL]-ACRILICO QUE SE ADMINISTRA EN UNA CANTIDAD DE 800MG A 2400MG POR DIA; Y OPCIONALMENTE C) RIBAVIRINA. TAMBIEN SE REFIERE A UN METODO DE TRATAMIENTO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE INFECCION POR EL VIRUS DE LA HEPATITIS C (HCV)
PE2013000657A 2010-09-30 2011-09-23 Terapia de combinacion para tratar infeccion por hcv PE20131397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38825310P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
PE20131397A1 true PE20131397A1 (es) 2014-01-04

Family

ID=44735903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000657A PE20131397A1 (es) 2010-09-30 2011-09-23 Terapia de combinacion para tratar infeccion por hcv

Country Status (21)

Country Link
US (1) US20120135949A1 (es)
EP (1) EP2621495A1 (es)
JP (1) JP2013540112A (es)
KR (1) KR20130116245A (es)
CN (1) CN103228278A (es)
AP (1) AP2013006734A0 (es)
AU (1) AU2011310761A1 (es)
BR (1) BR112013007423A2 (es)
CA (1) CA2813093A1 (es)
CL (1) CL2013000670A1 (es)
CO (1) CO6700843A2 (es)
EA (1) EA201300421A1 (es)
EC (1) ECSP13012551A (es)
MA (1) MA34547B1 (es)
MX (1) MX2013003060A (es)
PE (1) PE20131397A1 (es)
PH (1) PH12013500559A1 (es)
SG (1) SG188238A1 (es)
TW (1) TW201306839A (es)
WO (1) WO2012041771A1 (es)
ZA (1) ZA201300992B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013147749A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7027A (en) * 1850-01-15 Circulak
US10006A (en) * 1853-09-06 Improvement in printer s ink
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EA009295B1 (ru) 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
EP1651631A1 (en) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
CN103319464A (zh) * 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
AU2006213769B2 (en) 2005-02-11 2012-10-04 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
AU2006261132A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR073603A1 (es) * 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
AU2009316755B2 (en) 2008-11-21 2015-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition of a potent HCV inhibitor for oral administration
UA104195C2 (ru) 2009-07-07 2014-01-10 Берингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция ингибитора протеазы вируса гепатита c

Also Published As

Publication number Publication date
TW201306839A (zh) 2013-02-16
CL2013000670A1 (es) 2013-08-09
JP2013540112A (ja) 2013-10-31
EP2621495A1 (en) 2013-08-07
MX2013003060A (es) 2013-05-30
ECSP13012551A (es) 2013-06-28
ZA201300992B (en) 2014-07-30
CO6700843A2 (es) 2013-06-28
SG188238A1 (en) 2013-04-30
BR112013007423A2 (pt) 2016-07-12
PH12013500559A1 (en) 2013-05-06
EA201300421A1 (ru) 2013-08-30
AU2011310761A1 (en) 2013-02-21
US20120135949A1 (en) 2012-05-31
CN103228278A (zh) 2013-07-31
CA2813093A1 (en) 2012-04-05
MA34547B1 (fr) 2013-09-02
WO2012041771A1 (en) 2012-04-05
KR20130116245A (ko) 2013-10-23
AP2013006734A0 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
PE20131397A1 (es) Terapia de combinacion para tratar infeccion por hcv
PE20150202A1 (es) Compuestos antivirales
PE20141056A1 (es) Metodos para el tratamiento de vhc
EA201690497A3 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201290993A1 (ru) Нуклеозидфосфорамидаты
EA201290053A1 (ru) Ингибиторы вирусов flaviviridae
MX375432B (es) Inhibidores de la replicacion de los virus de la gripe.
PE20150204A1 (es) Inhibidores de virus de hepatitis c
ECSP14013189A (es) Inhibidores de la replicación de los virus de la gripe
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201001274A1 (ru) Имидазолилбифенильные имидазолы в качестве ингибиторов вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201370017A1 (ru) Ингибиторы вируса гепатита с
TN2012000214A1 (en) Hepatitis c virus inhibitors
MY152971A (en) Hepatitis c virus inhibitors
PH12013501543A1 (en) Hepatitis c virus inhibitors
PE20080612A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
BR112014010401A2 (pt) inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
EA201391685A1 (ru) Ингибиторы вируса гепатита с
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
CL2011001764A1 (es) Composicion farmaceutica que comprende (2r,3r,4r,5r)-5-(4-amino-2-oxo-2h-pirimidin-1-il)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidro-furan-3-il ester de acido isobutirico e hidroxipropilcelulosa; y uso en el tratamiento de una enfermedad mediada por el virus de la hepatitis c.
CL2014001783A1 (es) Composicion farmaceutica liquida que comprende acido 1-{[4-[8-bromo-2-(2-isopropilcarbamoil-tiazol-4-il)-7-metoxi-quinolin-4-iloxi]-1-(r)-(2-ciclopentiloxicarbonilamino-3,3-(s)-dimetil-butiril)-pirrolidin-(s)-2-carbonil]-amino}-2-(s)-vinil-ciclopropan-(r)-carboxilico, inhibidor selectivo de la hcv ns3 serina proteasa; y metodo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal